New Study Demonstrates Significant Pain Relief for Patients with Metastatic Spinal Tumors after Treatment with the DFINE STAR™ Tumor Ablation System

SAN JOSE, Calif.--()--DFINE®, Inc., a market leader in the treatment of spinal diseases, today announced data from the American Society of Clinical Oncology 50th Annual Meeting in Chicago highlighting the benefits of Targeted Radiofrequency Ablation™ (t-RFA) therapy with the STAR™ Tumor Ablation System.

Investigators at the James Graham Brown Cancer Center in Louisville, KY concluded that t-RFA was effective in controlling pain in cancer patients with spinal metastasis.

The retrospective study of 37 patients treated with the STAR System demonstrated a statistically significant (p<0.05) reduction in mean pain scores from 8.2 pre-treatment to 1.0 at one week follow up.

“t-RFA using the STAR System represents a significant advancement in the treatment of limited bony metastases or when other therapies prove inadequate,” said Goetz H. Kloecker, MD, MPH, Associate Professor of Medicine and Director of the Medical Oncology/Hematology Fellowship Program at the James Graham Brown Cancer Center.

“We are excited to see further clinical evidence confirming the benefits of t-RFA,” said Greg Barrett, Chief Executive Officer of DFINE. “The procedure is an important option for cancer patients who are seeking rapid relief from painful spinal tumors.”

About STAR™ Tumor Ablation System

t-RFA with the STAR System does not treat cancer. It is cleared by the FDA for providing palliative treatment (e.g. pain relief) by ablation of metastatic malignant tumors in a vertebral body. For a complete list of indications, risks and contraindications, visit http://www.dfineinc.com/Product-Risk---SpineSTAR

About DFINE, Inc.

DFINE is dedicated to relieving pain and improving the quality of life for patients suffering from spinal diseases through innovative, minimally invasive therapies. The company’s flagship products, the StabiliT® Vertebral Augmentation System and STAR™ Tumor Ablation System, represent generational advancements in the minimally invasive treatment of spinal diseases. DFINE is based in San Jose, Calif. and is a privately held company.

DFINE and StabiliT are registered trademarks and STAR and Targeted Radiofrequency Ablation (t-RFA) are trademarks of DFINE, Inc.

Contacts

for DFINE, Inc.
Susan Benton Russell
Phone: 310.697.3488
susan@bentoncommunications.com

Contacts

for DFINE, Inc.
Susan Benton Russell
Phone: 310.697.3488
susan@bentoncommunications.com